Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,650	125 Pages	BCC Research	December, 2024	WA19463522

Best Price Guarantee
Price	from $4,650
Length	125 Pages
Publisher	BCC Research
Published Date	December, 2024
SKU	WA19463522

Table of Contents
Description

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

Report Scope

This report focuses on the global market for Alzheimer’s disease (AD) diagnostics and therapeutics, offering an updated review of this rapidly emerging market. In this report, the diagnostic market covers only biomarker tests for AD. Cognitive tests and neuroimaging diagnostic methods assessing structural changes are not part of the market calculations. The diagnostics market segmentation is based on the test type and region.

The therapeutics segment covers pharmacological treatments (drugs) only. This report does not cover alternative treatment options, such as procedural interventions. Additionally, many medications are used “off-label” to manage non-cognitive symptoms, such as agitation and depression, associated with dementia due to AD. This report does not cover off-label drugs used in the treatment of Alzheimer’s. The therapeutics market segmentation is based on purpose, drug class, drug type, disease stage, and region.

An analysis of clinical trials, innovations, opportunities, and the latest trends in the AD diagnostics and therapeutics market are also discussed in the report.

Report Includes

38 data tables and 80 additional tables

Analyses of the trends in the global market for Alzheimer’s disease (AD) therapeutics and diagnostics, with market revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecasts for 2024-2025, and projected CAGRs through 2029

Estimates of the size of the global market and revenue growth prospects, along with a market share analysis by type, therapeutic application, drug classification, mechanism of action, disease state of indication and region

Facts and figures pertaining to key market dynamics, technological advances, regulations, and the impact of macroeconomic factors

Identification of diagnostic tools and equipment; scientific and technological frameworks; drug profiles, clinical groundworks; and coverage of global developments

Information on products that are currently available for the diagnosis and treatment of Alzheimer’s disease, as well as the promising new drug candidates and diagnostic imaging agents

An analysis of patents, emerging trends and the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook

Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies

Profiles of leading companies, including AbbVie Inc., Biogen, Eisai Co. Ltd., Eli Lilly and Co., and F. Hoffmann-La Roche Ltd.

Companies Mentioned

ABBVIE INC.
ALPHA COGNITION
ALZPATH INC.
AUROBINDO PHARMA
BIOGEN
C2N DIAGNOSTICS
CORIUM LLC.
DIADEM SRL
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
H.U. GROUP HOLDINGS INC.
LABORATORY CORPORATION OF AMERICA HOLDINGS
LILLY
OTSUKA HOLDINGS CO. LTD.
QUEST DIAGNOSTICS INC.

Chapter 1 Executive Summary: Market Outlook; Scope of Report; Market Summary
Chapter 2 Market Overview: Alzheimer's Disease Overview; Alzheimer's Disease Pathophysiology; AD and Amyloid Cascade; AD and Tauopathy; AD and Neurotransmitter Systems; Diagnosis of AD; Cognitive Status Testing; Brain Imaging; Lumbar Puncture; Blood-Biomarker Tests; Genetic Testing; Pharmaceutical Treatment of AD
Chapter 3 Market Dynamics: Market Dynamics Snapshot; Market Drivers; Growing Incidence of AD; High Unmet Need; Growing Focus on Biomarkers in Diagnosis and Drug Development; Increasing Public and Private investment in Neuroscience; Growing Public Awareness and Early Diagnosis; Large Number of Drugs in Late-Stage Clinical Trials; Market Restraints; High Costs of Diagnostics and Novel Therapies; Patent Expirations of Branded Drugs and Emergence of Generics; High Failure Rate in Drug Development
Chapter 4 Emerging Technologies and Developments: Emerging Technologies/Trends; Blood Tests for AD Screening and Diagnosis; Disease Modifying Small-Molecule Drugs; Re-purposed Drugs; AI and Machine Learning; Pipeline Analysis; Overview; Therapeutic Purpose Type; Novel AD Therapeutics in Development in Phase 3; By Target Type; By Disease State; Novel PET Radiotracers in Development
Chapter 5 Market Segmentation Analysis: Segmentation Breakdown; Market Analysis, by Test Type; AD Biomarker Tests Market, by Test Type; AD Therapeutics Market, by Therapeutic Purpose; AD Therapeutics Market, by Drug Class; AD Therapeutics Market, by Drug Type; AD Therapeutics Market, by Disease Stage; Geographic Breakdown; Market Analysis, by Region; North America; Europe; Asia-Pacific; Rest of the World (RoW)
Chapter 6 Competitive Intelligence: AD Therapeutics; Alzheimer's Generic Drug Market; Alzheimer's Branded Drug Market; Donepezil; Rivastigmine; Galantamine; Memantine; Combination Therapy (Memantine and Donepezil); AD Diagnostics; Overview; Product Launches/Approvals in the AD Diagnostics Market
Chapter 7 Appendix: Methodology; Sources; Abbreviations; Company Profiles; ABBVIE INC.; ALPHA COGNITION; ALZPATH INC.; AUROBINDO PHARMA; BIOGEN; C2N DIAGNOSTICS; CORIUM LLC.; DIADEM SRL; EISAI CO. LTD.; F. HOFFMANN-LA ROCHE LTD.; H.U. GROUP HOLDINGS INC.; LABORATORY CORPORATION OF AMERICA HOLDINGS; LILLY; OTSUKA HOLDINGS CO. LTD.; QUEST DIAGNOSTICS INC.